Atrial Fibrillation Ablation Registry

Overview

The Atrial Fibrillation Ablation Registry (AFib Ablation Registry™) is designed to assess the prevalence, demographics, management, and outcomes of patients undergoing percutaneous catheter ablation procedures to treat atrial fibrillation (AF).

Full Title of Study: “Atrial Fibrillation Ablation Registry Protocol Number: 3122-2016″

Study Type

  • Study Type: Observational [Patient Registry]
  • Study Design
    • Time Perspective: Other
  • Study Primary Completion Date: May 20, 2025

Detailed Description

The Atrial Fibrillation Ablation Registry (AFib Ablation Registry™) is designed to assess the prevalence, demographics, management, and outcomes of patients undergoing percutaneous catheter ablation procedures to treat atrial fibrillation (AF). Patient-level data will be submitted by participating hospitals on a quarterly basis to the American College of Cardiology Foundation's National Cardiovascular Data Registry (NCDR™). The primary aims of the AFib Ablation Registry are to optimize the outcomes and management of patients through the implementation of evidence-based guideline recommendations in clinical practice, facilitate efforts to improve the quality and safety for patients undergoing percutaneous catheter ablation procedures, investigate novel quality improvement methods and provide risk-adjusted assessment of patients for comparison with nationwide NCDR data. The secondary purpose of the AFib Ablation Registry is to serve as a rich source of clinical data to support assessments of short- and long-term safety, comparative and cost effectiveness research, and as a scalable data infrastructure for post market studies.

Interventions

  • Device: Atrial Fibrillation Ablation
    • A procedure used to treat an irregular heart rhythm (arrhythmia)

Clinical Trial Outcome Measures

Primary Measures

  • Unsuccessful treatment rate
    • Time Frame: 1 year
    • measured by the number of repeated procedure

Secondary Measures

  • Adverse Events
    • Time Frame: 1 year
    • Number of participants with adverse events that are related to treatment (i.e. cardiac tamponade, periprocedural stroke, pulmonary vein stenosis, esophageal damage, etc)

Participating in This Clinical Trial

Inclusion Criteria

  • Adult patients, 18 years and older, undergoing percutaneous catheter ablation procedures to treat atrial fibrillation

Exclusion Criteria

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Hoag Memorial Hospital Presbyterian
  • Provider of Information About this Clinical Study
    • Principal Investigator: Colleen Balius, Clinical Data Coordinator – Hoag Memorial Hospital Presbyterian

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.